The tweet was deleted by the author.
But we saved everything 🙂.
REGENXBIO is focusing efforts on developing gene therapies to address diabetic retinopathy, a complication faced by up to 25% of individuals with diabetes.
This condition is a leading cause of vision loss among adults, yet only approximately 60% of diabetics receive recommended annual eye exams. As November marks Diabetes Awareness Month, the company is highlighting its commitment to creating innovative solutions to help preserve vision for those affected.
REGENXBIO's targeted approach to diabetic retinopathy highlights the company's broader influence in advancing biopharma innovation, as reflected in its active participation within the evolving biopharma ecosystem discussions. For a deeper look at how REGENXBIO's leadership is shaping the future of healthcare, see their role in recent biopharma ecosystem discussions.